设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至[email protected]

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:中国医师协会
总编辑(兼编辑部主任):

杨秋
副总编辑:魏永祥、张运、

罗毅、谭学瑞、唐来坤、

王喜艳

编辑部副主任:杨水霞
邮发代号:80-528
定价:18.00元
全年:216.00元
Email:[email protected]
电话(传真):010-64428528;
010-64456116(总编室)

                  

过刊目录

2019 年第 4 期 第 14 卷

氯吡格雷与替格瑞洛对冠状动脉旁路移植术后桥血管通畅性的影响比较

Effects of clopidogrel versus ticagrelor on graft patency after coronary artery bypass grafting

作者:王德广周玉杰刘妍赵奇马越彭文龙张敬林朱勇刘猛刘晓丽周志明

英文作者:

单位:100029首都医科大学附属北京安贞医院心内十二病房北京市心肺血管疾病研究所

英文单位:

关键词:冠状动脉旁路移植术;抗血小板治疗;氯吡格雷;替格瑞洛;桥血管通畅性

英文关键词:

  • 摘要:
  • 【摘要】

    【摘要】目的    比较冠状动脉旁路移植术(CABG)后患者应用替格瑞洛联合阿司匹林与氯吡格雷联合阿司匹林治疗1年对桥血管通畅性的影响。方法    收集2016年1月至2017年6月在首都医科大学附属北京安贞医院住院治疗,成功完成CABG,且术后给予双联抗血小板治疗的576例冠状动脉粥样硬化性心脏病患者的临床资料。根据术后双联抗血小板治疗用药分为替格瑞洛组(283例)与氯吡格雷组(293例)。比较2组患者治疗1年后桥血管通畅率、主要不良心血管事件(MACE)发生率和出血事件发生率。结果    替格瑞洛组共完成随访264例,氯吡格雷组共完成随访269例。共计1 652支桥血管被评估,其中氯吡格雷组834支,替格瑞洛组818支。替格瑞洛组1年后桥血管通畅率与氯吡格雷组比较[88.5%(724/818)比85.5%(713/834)],差异无统计学意义(P=0.068)。术后1年,2组患者MACE发生率比较,差异无统计学意义(P=0.571)。替格瑞洛组非CABG相关出血事件发生率明显高于氯吡格雷组[19.3%(51/264)比11.5%(31/269)],差异有统计学意义(P=0.013)。结论    对于CABG术后双联抗血小板治疗的冠状动脉粥样硬化性心脏病患者,氯吡格雷与替格瑞洛在术后1年桥血管通畅率方面无明显差异,而对于患者远期预后及出血事件评估尚需进一步研究。

  • 【Abstract】Objective    To compare the effects of ticagrelor and aspirin versus clopidogrel and aspirin on 1 year graft patency after coronary artery bypass grafting(CABG). Methods    From January 2016 to June 2017, 576 patients with coronary atherosclerotic heart disease were successfully treated by CABG in Beijing Anzhen Hospital, Capital Medical University, and received double antiplatelet therapy after operation. According to the antiplatelet regimen, the patients were divided into ticagrelor group (283 cases) and clopidogrel group(293 cases). Patency rate of bridge vessels, incidences of major adverse cardiovascular events(MACE) and bleeding events were analyzed 1 year after operation. Results    Postoperative follow-up was completed in 264 cases in ticagrelor group and 269 cases in clopidogrel group. A total of 1 652 bridge vessels including 834 in clopidogrel group and 818 in ticagrelor group were assessed. There was no significant difference of the 1 year patency rate of bridge vessels between ticagrelor group and clopidogrel group[88.5% (724/818) vs 85.5% (713/834)](P=0.068). There was no significant difference of incidence of MACE between groups(P=0.571). Incidence of non-CABG-related bleeding events in ticagrelor group was significantly higher than that in clopidogrel group[19.3%(51/264) vs 11.5%(31/269)](P=0.013). Conclusions    There is no significant difference between ticagrelor+aspirin and clopidogrel+aspirin on graft patency in 1 year after CABG. Further researches are needed to assess the long-term prognosis and bleeding risk.

copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: [email protected]
网址:www.chinamedicinej.com 京ICP备10041176号-1
本系统由北京博思汇文数字科技有限公司设计开发 技术服务电话:400-921-9838
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱[email protected]







安卓


苹果

关闭